Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

@article{Primrose2014SystemicCW,
  title={Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.},
  author={John Neil Primrose and Stephen Falk and Meg Finch-Jones and Juan Valle and D O'reilly and Ajith Siriwardena and Joanne Hornbuckle and Mark Peterson and Myrddin Rees and Tim Iveson and Tamas Hickish and Rachel Butler and Louise Stanton and E. Dixon and Louisa Little and Megan Bowers and Si{\^a}n A Pugh and Oliver J Garden and D. Cunningham and Tim Maughan and John A Bridgewater},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 6},
  pages={601-11}
}
BACKGROUND Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to these chemotherapy regimens results in an overall survival advantage in patients with advanced disease who have the KRAS exon 2 wild-type tumour genotype. We aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 94 extracted citations

A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2016
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab in resected stage III colon cancer

J Taïeb, J Tabernero, E Mini
Ann Oncol • 2013

Similar Papers

Loading similar papers…